Evidence map›Paper›PMID 23211261›Full record

ArticleThe British journal of general practice : the journal of the Royal College of General Practitioners2012

Achievement of cholesterol targets and prescribing of higher-cost statins: a cross-sectional study in general practice.

Robert Fleetcroft, Peter Schofield, Martin Duerden, Mark Ashworth

Abstract read
In one paragraph

Article in The British journal of general practice : the journal of the Royal College of General Practitioners, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Robert FleetcroftDepartment of Population Health and Primary Care, Norwich Medical School, University of East Anglia, Norwich. r.fleetcroft@uea.ac.uk
Peter Schofield
Martin Duerden
Mark Ashworth

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is conflicting evidence as to whether achievement of cholesterol targets at the population level is dependent on the choice and cost of statin.

aimTo investigate the practice-level relationship between cholesterol quality indicators in patients with heart disease, stroke, and diabetes and prescribing of low-cost statins. DESIGN AND

settingCorrelations and linear regression modelling of retrospective cross-sectional practice-level data with potential explanatory variables in 7909 (96.4%) general practices in England in 2008-2009.

methodQuality indicator data were obtained from the Information Centre and prescribing data from the NHS Business Authority. A 'cholesterol quality indicator' score was constructed by dividing the numbers of patients achieving the target for cholesterol control of ≤5 mmol/l in stroke, diabetes, and heart disease by the numbers on each register. A 'low-cost statin' ratio score was constructed by dividing the numbers of defined daily doses of simvastatin and pravastatin by the total numbers of defined daily doses of statins.

resultsSimvastatin accounted for 83.3% (standard deviation [SD] = 15.7%) of low-cost statins prescribed and atorvastatin accounted for 85.7% (SD = 14.8%) of high-cost statins prescribed. The mean cholesterol score was 73.7% (SD = 6.0%). Practices using a higher proportion of the low-cost statins were less successful in achieving cholesterol targets. An increase of 10% in the prescribing of low-cost statins was associated with a decrease of 0.46% in the cholesterol quality indicator score (95% confidence interval = -0.54% to -0.38%, P<0.001).

conclusionGreater use of low-cost statins was associated with a small reduction in cholesterol control.

Indexed as

AdultCosts and Cost AnalysisCross-Sectional StudiesDiabetes MellitusEnglandGeneral PracticeHeart DiseasesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaPractice Patterns, Physicians'Quality Indicators, Health CareStrokeHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID23211261
PMCPMC3505414

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.